Tracking MS changes with ofatumumab in active relapsing MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at whether blood tests and eye-tracking tasks can show how well ofatumumab slows or stops MS damage. It's for people starting ofatumumab as part of their regular care who have active relapsing-remitting MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have been prescribed ofatumumab for your MS but haven't started it yet.
- You have active relapsing-remitting MS (RRMS), meaning you still have relapses or new MRI lesions.
- Your disability score (EDSS) is between 0 and 7 at the time you start the study.
- You can give blood samples and understand written and spoken English or French.
- You are not pregnant or breastfeeding, and if you could become pregnant, you use effective birth control while taking ofatumumab and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
This study looks at what happens to infection-fighting antibody levels when people with relapsing multiple sclerosis switch from ocrelizumab to ofatumumab. It may help doctors understand if switching is a good option for people whose antibody levels are low.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Hear when a new Relapsing Remitting Multiple Sclerosis (RRMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.